The notices it replaced
- Reissues: PAR-21-294 Molecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed)
Who won it before
3 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $1,851,969 in first-year total cost, median $649,473.
Most frequent study sections
- Cancer Biomarkers Study Section[CBSS]1
- Special Emphasis Panel[ZRG1 TIR-W (01)]1
- Therapeutic Immune Regulation Study Section[TIR]1
Most frequent institutions
- UNIVERSITY OF CALIFORNIA, SAN FRANCISCO1
- UNIVERSITY OF LOUISVILLE1
- UNIVERSITY OF TX MD ANDERSON CAN CTR1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2025 | Early identification of immunotherapy resistance through integrated multiparameter imaging1R01CA290027-01A1 · under PAR-21-294 | ANWAR, MEKHAILSPITZER, MATTHEW | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $676,006 | TIR |
| 2024 | Understanding Pancreatic Cancer Immune Microenvironment and Treatment Response through Integrating in vivo Imaging with Immunophenotyping1R01CA278941-01A1 · under PAR-21-294 | GUO, HAIXUNYAN, JUN | UNIVERSITY OF LOUISVILLE, KY | $649,473 | ZRG1 |
| 2022 | [18F]4FN PET Imaging of Innate Immunity Activation During Immunotherapy-Induced Adverse Events1R01CA273130-01 · under PAR-21-294 | NEELAPU, SATTVA SPIWNICA-WORMS, DAVID | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $526,490 | CBSS |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.